Legend Biotech - ADR opened lower at $19.10, compared with its previous close of $19.54. In the last trading session, the stock traded between $17.86 and $19.13. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Legend Biotech - ADR is now worth
$ 38.66
Resulting in a loss of
$ 61.34 (61.34%)
Note: Past profits do not guarantee future returns.
Rating from 9 Analysts
Today's Change
$-1.00 (-5.12%)
Day High
$19.13
Day Low
$17.86
Day Open
$19.10
Prev Close
$19.54
Volume
40,96,824
1W Return
-18.60%
1M Return
4.19%
3M Return
-15.20%
6M Return
-27.53%
1Y Return
-42.12%
Market Cap ($ Mn)
3,606
PE Ratio
-
PB Ratio
3.33
PEG Ratio
-
ROE
-31.49%
ROCE
-22.91%
EPS (TTM)
$0.13
1 Week
-18.60%
1 Month
4.19%
3 Months
-15.20%
6 Months
-27.53%
9 Months
-0.01%
Morgan Stanley and Barclays cut Legend Biotech targets, keep overweight
Morgan Stanley lowers Legend Biotech price target from $49 to $43. Barclays cuts Legend Biotech price target from $68 to $61. Both Morgan Stanley and Barclays maintain Overweight ratings on the stock.
YesterdayLegend Biotech reports 50% five-year PFS for CARVYKTI
50% of patients remained progression-free five years post-CARVYKTI infusion. Five-year overall survival rate was 69.2% in CARTITUDE-2 Cohort A. Median progression-free survival reached 60.5 months with no new neurotoxicity. One case of acute myeloid leukemia reported since previous analysis.
1mo agoLegend Biotech appoints Alan Bash interim CEO after Huang exits
Legend Biotech Corporation (NASDAQ: LEGN) has appointed Alan Bash as Interim Chief Executive Officer following the departure of founder Ying Huang, who stepped down from his CEO and Board roles effective July 24, 2026. Huang will serve as an advisor through August 2026 to facilitate a smooth transition, while the Board initiates a search for a permanent successor. The leadership change comes as the company focuses on expanding access to its flagship cell therapy, CARVYKTI.
3mo agoJP Morgan reinstates Neutral on Legend Biotech with $35 target
JP Morgan analyst Jessica Fye reinstated a Neutral rating on Legend Biotech (NASDAQ: LEGN) and announced a price target of $35.
4mo agoLegend Biotech prices $226M public offering of ADSs
Legend Biotech Corporation priced a public offering of 7.7 million ADSs at $29.35 per share, aiming to raise $226 million in gross proceeds, causing a premarket stock decline. The company reported Q1 revenue of $305.1 million and holds $834.6 million in cash, with plans to use the offering proceeds for general corporate purposes.
4mo agoLegend Biotech reports 100% ORR for LB2501 in R/R B-NHL
Legend Biotech's LB2501 achieved a 100% ORR and 83.3% CR rate at DL2 in a Phase 1 study for R/R B-NHL, with a favorable safety profile and no dose-limiting toxicities. The therapy demonstrated dose-dependent in vivo CAR-T expansion without lymphodepletion, supporting further investigation as a novel treatment approach.
5mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Legend Biotech - ADR is now worth
$ 38.66
Resulting in a loss of
$ 61.34 (61.34%)
Note: Past profits do not guarantee future returns.
